Ep. 173 Why a Nasdaq Biotech Is Building a Prediction Markets Treasury

Today’s conversation focuses on one of the more unique stories in the market: a Nasdaq-listed biotech company combining its clinical-stage immunotherapy pipeline with a first-of-its-kind prediction markets digital asset treasury strategy built around the RAIN protocol. We discuss why prediction markets are gaining momentum, how Rain fits into the broader market infrastructure layer, what AI-generated prediction markets could unlock, and how token mechanics like buy-and-burn may matter for long-term holders. We also touch on Allocetra, Enlivex’s clinical-stage therapy, the regulatory backdrop for prediction markets, and what the next 6 to 12 months could look like for the category. Social Media: Youtube: https://www.youtube.com/@TheCryptoMavericks Twitter: https://twitter.com/TheCryptoMavs Instagram: https://www.instagram.com/TheCryptoMavericks TikTok: https://www.tiktok.com/@TheCryptoMavericks Guest Links: https://x.com/sumsub sumsub.com **THIS IS NOT FINANCIAL OR LEGAL ADVICE** © Copyright 2025 Boardwalk Flock, LLC All Rights Reserved ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ Podcast Music: Vinyl Moonlight by Pop Villains License #4470913 Licensed from PremiumBeat.com ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬